10-K: BioCorRx Inc. Reports Annual Results for Fiscal Year Ended December 31, 2024, Highlights Ongoing Research and Development

BioCorRx Inc. reports its annual results for the fiscal year ended December 31, 2024, detailing financial performance, research and development activities, and strategic initiatives.

Summary

• BioCorRx Inc. reported a net loss attributable to BioCorRx Inc. of $5,106,124, or ($0.49) per share, for the year ended December 31, 2024, compared to a net loss of $3,766,913, or ($0.45) per share, for the year ended December 31, 2023.
• The company's total net revenues for 2024 were $7,665, a significant decrease from $89,160 in 2023.
• Operating expenses increased to $5,130,170 in 2024 from $3,876,956 in 2023, primarily due to higher stock-based compensation, accounting and legal fees, and research and development expenses.
• The company recognized grant income of $1,473,276 in 2024, compared to $932,996 in 2023, reflecting increased funding for BICX104 research.
• BioCorRx Pharmaceuticals Inc., a subsidiary, was awarded a grant of $11,029,977 from NIDA for research on BICX104 for methamphetamine use disorder.
• The company is focused on developing addiction treatment solutions, including the Beat Addiction Recovery Program and UnCraveRx Weight Loss Program.
• The company is also pursuing FDA approval for BICX104, an implantable naltrexone pellet for treating alcohol and opioid use disorders.
• The company's independent registered public accounting firm has expressed substantial doubt regarding its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company secured a significant grant and is pursuing innovative treatment solutions, the financial results are weak, and the auditor has raised concerns about the company's ability to continue as a going concern. This suggests a cautious outlook.

Positives

• BioCorRx Pharmaceuticals Inc. secured an $11,029,977 grant from NIDA to support research on BICX104 for methamphetamine use disorder.
• Grant income increased to $1,473,276 in 2024 from $932,996 in 2023, providing additional resources for research and development.
• The company is actively developing addiction treatment solutions, including the Beat Addiction Recovery Program and UnCraveRx Weight Loss Program.
• The company is pursuing FDA approval for BICX104, an implantable naltrexone pellet for treating alcohol and opioid use disorders.

Negatives

• The company reported a net loss attributable to BioCorRx Inc. of $5,106,124, or ($0.49) per share, for the year ended December 31, 2024, compared to a net loss of $3,766,913, or ($0.45) per share, for the year ended December 31, 2023.
• Total net revenues decreased significantly to $7,665 in 2024 from $89,160 in 2023.
• Operating expenses increased to $5,130,170 in 2024 from $3,876,956 in 2023, driven by higher stock-based compensation, accounting and legal fees, and research and development expenses.
• The company's independent registered public accounting firm has expressed substantial doubt regarding its ability to continue as a going concern.

Risks

• The company has a history of operating losses and may never be profitable.
• The company needs substantial capital to implement its sales distribution strategy and to develop and commercialize future products.
• If more licensed providers do not agree to offer the company's programs to their patients, the programs may not achieve market acceptance.
• The use of the company's programs could result in product liability or similar claims.
• The company's success is substantially dependent on the continued service of its senior management.
• The unavailability, reduction or elimination of government incentives could have a material adverse effect on the company's business.
• The company is subject to regulations of various local and federal government agencies.
• The commercial success of the company's programs and products will depend upon the degree of market acceptance by physicians, hospitals, third-party payors, and others in the medical community.
• The company may not be able to protect or enforce its intellectual property rights.
• The company operates in a highly competitive industry.
• The company's share price could be volatile and its trading volume may fluctuate substantially.
• The company's Common Stock has in the past been subject to the Penny Stock rules of the SEC and the trading market in the company's securities is limited.
• The company faces risks related to Novel Coronavirus (COVID-19) which could significantly disrupt the company's research and development, operations, sales, and financial results.

Future Outlook

The Company anticipates that it will continue to incur operating losses as it executes its development plans for 2025, as well as other potential strategic and business development initiatives. Management has developed a plan to continue operations, develop its products, and acquire technologies and assets. This plan includes continued control of expenses and obtaining equity or debt financing.

Industry Context

BioCorRx operates in the addiction treatment and weight loss industries, which are characterized by increasing demand due to rising rates of substance use disorders and obesity. The company faces competition from established pharmaceutical companies, rehabilitation centers, and weight loss programs. The company's focus on medication-assisted treatment and innovative delivery methods, such as implantable naltrexone, positions it to potentially capture a share of these growing markets.

Comparison to Industry Standards

• BioCorRx's financial performance lags behind industry leaders in the addiction treatment and pharmaceutical sectors.
• Companies like Indivior and Alkermes, which market opioid dependence treatments, have significantly higher revenue and market capitalization.
• In the weight loss market, companies like WW International (formerly Weight Watchers) and Nutrisystem demonstrate stronger financial performance and brand recognition.
• BioCorRx's reliance on grant funding for research and development is common in the pharmaceutical industry, but its ability to secure additional funding and achieve commercial success will be critical for its long-term viability.
• The company's focus on innovative delivery methods, such as implantable naltrexone, differentiates it from competitors but also introduces regulatory and manufacturing risks.

Management Changes

Legal Proceedings

• The Company initiated litigation in 2019 based on a claim that Pellecome and Dr. Orbeck utilized the Companys confidential information to advance their own weight loss product.
• The Company dismissed this litigation without prejudice in July 2021.
• On March 30, 2022, the court entered judgment in favor of Pellecome as an individual defendant whereby the Company was ordered to pay Pellecome total costs and attorneys fees of $235,886.
• On January 5, 2024 the California Superior Court for Orange County entered an amended judgement of $332,503 in favor of Pellecome for costs and attorneys fees, in addition to the $332,503 judgement the Company owes accrued interest of $87,639.
• As of December 31, 2024, the Company has accrued $323,184 as a loss contingency for this matter.

Related Party Transactions

• On November 9, 2023, the Company entered into a Subscription Agreement (the 2023 Q4 Galligan Subscription Agreement) with the J and R Galligan Revocable Trust, managed by Mr. Galligan, a holder of between 15% and 20% of the Companys shares of common stock and a member of the Companys Board of Directors.
• On November 9, 2023, the Company entered into a Subscription Agreement (the 2023 Q4 Lucido Subscription Agreement) with Louis C Lucido.
• As of December 31, 2024 and 2023, the Company owed $302,749 and $136,273 advances to Lourdes Felix, respectively.
• Since September 2022, the Company had received an aggregate of $879,026 advances from Louis C Lucido, a member of the Companys Board of Directors.
• On August 29, 2023, the Company issued an unsecured promissory note payable to Louis C Lucido for $150,000 with principal and interest due August 29, 2024, with a stated interest rate of 8% per annum.
• On April 24, 2024, the Company entered into an Exchange Agreement (the Louis 2024 Exchange Agreement) with Mr. Lucido, pursuant to which Mr. Lucido agreed to exchange of the promissory note then outstanding of $150,000 and the related party advances of $296,426 and the accrued interest on the promissory note of $7,858 and director fees of $90,000 into the Companys 460,477 shares of common stock at a price of $1.18 per share.
• On October 14, 2024, the Company entered into an Exchange Agreement (the Louis 2024 Q4 Exchange Agreement) with Mr. Lucido, pursuant to which Mr. Lucido agreed to exchange of the related party advances of $357,600 and director fees of $30,000 into the Companys 1,105,218 shares of common stock at $0.35 per share.
• On April 24, 2024, the Company entered into an Exchange Agreement (the Lourdes 2024 Exchange Agreement) with Lourdes Felix, the Companys Chief Executive Officer and Chief Financial Officer, pursuant to which Lourdes Felix agreed to exchange of the director fees of $265,000 into the Companys 224,196 shares of common stock at $1.18 per share.

Stakeholder Impact

• Shareholders: The net loss and going concern warning may negatively impact shareholder value.
• Employees: Potential cost-cutting measures to address financial challenges could affect employees.
• Customers: Continued development of addiction treatment and weight loss programs aims to benefit customers.
• Suppliers: The company's ability to meet its financial obligations to suppliers may be affected by its financial condition.
• Creditors: The company's ability to repay its debts is uncertain due to its financial challenges.

Next Steps

• Continue research and development efforts for BICX104.
• Seek FDA approval for BICX104.
• Implement sales and marketing strategies for the Beat Addiction Recovery Program and UnCraveRx Weight Loss Program.
• Secure additional financing to fund operations and development activities.
• Control expenses to improve financial performance.

Key Dates

Keywords

BioCorRx, Naltrexone, Addiction Treatment, BICX104, Opioid Use Disorder, Alcohol Use Disorder, Methamphetamine Use Disorder, MUD, OUD, FDA Approval, Financial Results, Research and Development, Grant Funding, Going Concern, Cognitive Behavioral Therapy, CBT, UnCraveRx, Weight Loss, Pharmaceuticals